Polling Questions

According to the webcast, Investigational Treatment Options for HSDD: New Avenues with Leonard Derogatis, PhD, In two Phase 3 clinical studies in premenopausal women with hypoactive sexual desire disorder (HSDD), bremelanotide:
 a. Confirmed a statistically significant, clinically meaningful increase in desire, and decrease in distress compared with placebo at 24 weeks
 b. Confirmed improvements in other components of sexual functioning, arousal, lubrication, and orgasm
 c. Produced ratings of overall satisfaction and treatment benefits that were significantly better than those of placebo
 d. All of the above

Your answers are confidential and will be used for educational purposes only.